Focused On-demand Library for SH2 domain-containing protein 1A

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries for protein-protein interfaces.

 Fig. 1. The sreening workflow of Receptor.AI

It features thorough molecular simulations of the target protein, both isolated and in complex with key partner proteins, complemented by ensemble virtual screening that accounts for conformational mobility in the unbound and complex states. The tentative binding sites are explored on the protein-protein interaction interface and at remote allosteric locations, encompassing the entire spectrum of potential mechanisms of action.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.







Alternative names:

Duncan disease SH2-protein; Signaling lymphocytic activation molecule-associated protein; T-cell signal transduction molecule SAP

Alternative UPACC:

O60880; A8MSW0; O95383; O95384; O95385; O95386; Q6FGS6; Q9UNR0


The SH2 domain-containing protein 1A plays a pivotal role in the immune system, acting as a cytoplasmic adapter that regulates receptors of the signaling lymphocytic activation molecule (SLAM) family. It is involved in the positive regulation of natural killer (NK) cell functions and enhances NK cell-mediated cytotoxicity. This protein is also known by alternative names such as Duncan disease SH2-protein and Signaling lymphocytic activation molecule-associated protein.

Therapeutic significance:

SH2 domain-containing protein 1A is linked to Lymphoproliferative syndrome, X-linked, 1, a rare immunodeficiency with severe outcomes. Understanding the role of this protein could open doors to potential therapeutic strategies for managing this condition and improving patient outcomes.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.